Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

Rangering i aksjer #3262
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Aksjekurs
$118.96
Markedsverdi
$5.41B
Endring (1 dag)
0.39%
Endring (1 år)
134.59%
Land
US
Handel Haemonetics Corporation (HAE)

Kategori

Healthcare
Antall utestående aksjer for Haemonetics Corporation (HAE)
Antall utestående aksjer per June 2026: 45.36M
Ifølge Haemonetics Corporation sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 45.36M. Ved slutten av March 2024 hadde selskapet 50.71M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Haemonetics Corporation (HAE) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 45.36M -9.87%
2025 50.33M -0.74%
2024 50.71M -0.15%
2023 50.78M -0.52%
2022 51.05M 0.71%
2021 50.69M -0.01%
2020 50.69M -1.63%
2019 51.53M -2.32%
2018 52.76M 2.43%
2017 51.51M 1.17%
2016 50.91M -1.21%
2015 51.53M -0.15%
2014 51.61M 0.51%
2013 51.35M 1.22%
2012 50.73M 1.14%
2011 50.15M -1.47%
2010 50.90M 0.24%
2009 50.78M -1.68%
2008 51.65M -3.45%
2007 53.49M 1.01%
2006 52.96M 3.74%
2005 51.05M 4.45%
2004 48.87M -0.63%
2003 49.18M -6.19%
2002 52.43M 3.62%
2001 50.60M -3.02%
2000 52.17M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
1.74B 3,742.62%
US
1.28B 2,726.44%
IE
383.50M 745.44%
US
1.48B 3,157.42%
US
- -
DE